Dihydroergotamine Dry Powder Inhalation for Migraine Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of dihydroergotamine (DHE) for migraine treatment suffer from poor bioavailability, complex administration methods, and significant side effects, limiting its widespread use and self-administration capabilities.
Innovation Solution
Development of dry powder formulations comprising DHE or its salts, hydrates, or polymorphs, combined with monovalent metal cations and excipients like leucine and mannitol, designed for inhalation, which provide rapid and effective migraine relief with minimized side effects and simplified administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If DHE is administered by injection in a clinical setting, then rapid and effective migraine treatment is achieved, but patient self-administration is precluded and side effects increase
Solution Approach 1:
The patent replaces the mechanical injection system with an inhalation-based dry powder delivery system. The dry powder inhaler uses patient's own inhalation effort to deliver the medication, eliminating the need for needle injection while maintaining rapid drug delivery to the bloodstream through pulmonary absorption.
Solution Approach 2:
The patent introduces the lungs as an intermediary organ for drug delivery. Instead of direct intravenous injection or oral administration, the dry powder formulation is inhaled and absorbed through the pulmonary system, serving as a middle ground that provides rapid onset like injection while enabling self-administration.
2Ease of operation
If propellant-based DHE formulations are used for oral inhalation, then self-administration is enabled, but device complexity and coordination difficulty increase
Solution Approach 1:
The patent removes the propellant component from the inhalation system, eliminating the need for pressurized canisters and complex actuation mechanisms. The dry powder formulation is delivered using only the patient's inhalation effort, simplifying the device to a passive delivery system without moving parts or coordination requirements.
Solution Approach 2:
The patient's own inhalation effort serves as the driving force for medication delivery. The dry powder inhaler is designed to be activated automatically by the patient's breath, eliminating the need for manual actuation or coordination between device operation and breathing maneuvers.
3Ease of operation
If pressurized inhalers are used for DHE administration, then drug delivery is enabled, but dosing consistency and delivery efficiency decrease
Solution Approach 1:
The patent changes the physical state of the medication from liquid (in propellant-based formulations) to dry powder form. This parameter change enables more precise dosing control, as the dry powder can be accurately measured and delivered in consistent amounts without the variability associated with propellant suspension mixing and atomization.
4Ease of operation
If nasal-spray formulations of DHE are used, then self-administration is enabled, but bioavailability decreases and side effects increase
Solution Approach 1:
The patent utilizes the pulmonary system's natural airflow and large surface area for rapid drug absorption. The inhalation route delivers the medication directly to the lungs where it is quickly absorbed into the bloodstream, providing bioavailability comparable to intravenous injection while avoiding the nasal mucosa's limitations.
Data Source
AI summary
The present disclosure relates to dry powder formulations comprising respirable dry particles that comprise 1) dihydroergotamine (DHE) or a salt, hydrate, or polymorph thereof, 2) a monovalent metal cation salt, and 3) one or more excipients; and also relates to methods of using the dry powder for the treatment of a migraine, headache, or a symptom thereof, methods of making the dry powder, and receptacles and devices containing the dry powder.